## First-Line H. pylori Eradication Regimen in India **Key Point:** In the Indian context, Omeprazole + Amoxicillin + Metronidazole (OAM triple therapy) is the most widely recommended and commonly used first-line regimen for H. pylori eradication, as endorsed by the Indian Academy of Gastroenterology (IAG) guidelines, owing to cost-effectiveness, availability, and the local resistance landscape. ### Why OAM Triple Therapy is Preferred in India 1. **Cost and Availability:** All three drugs are inexpensive, widely available across India, and well-tolerated, making this regimen accessible at all levels of healthcare. 2. **Clarithromycin Resistance:** Clarithromycin resistance in India ranges from 15–40% in various studies, making OAC (omeprazole + amoxicillin + clarithromycin) less reliable as a universal first-line choice. OAM avoids this concern. 3. **Metronidazole Resistance:** Although metronidazole resistance is reported at 30–50% in India, the combination with a PPI and amoxicillin still achieves eradication rates of 80–90% due to synergistic bactericidal activity and the acid-suppressive environment created by the PPI. 4. **IAG Endorsement:** The Indian Academy of Gastroenterology guidelines recommend OAM triple therapy (10–14 days) as the standard first-line regimen in India, particularly in resource-limited settings. ### Comparison of Regimens | Regimen | Composition | Eradication Rate | Indian Context | |---------|-------------|------------------|----------------| | **OAM (Triple)** | PPI + amoxicillin + metronidazole | 80–90% | **Preferred first-line (IAG)** | | **OAC (Triple)** | PPI + amoxicillin + clarithromycin | 85–95% | Acceptable where clarithromycin resistance is low | | **Bismuth Quadruple** | PPI + bismuth + tetracycline + metronidazole | 90–95% | Rescue/second-line therapy | | **Levofloxacin-based** | PPI + amoxicillin + levofloxacin | 85–90% | Salvage after first-line failure | **High-Yield:** Per IAG guidelines and standard Indian pharmacology texts (KD Tripathi, Essentials of Medical Pharmacology), OAM triple therapy for 10–14 days remains the recommended first-line regimen in India. Bismuth quadruple therapy is reserved for clarithromycin-resistant cases or after first-line failure. **Clinical Pearl:** Compliance is critical — patients must complete the full 10–14 day course. Partial adherence leads to treatment failure and promotes resistance selection. Post-treatment confirmation of eradication (urea breath test or stool antigen test, ≥4 weeks after therapy) is recommended. **Mnemonic:** **OAM** — **O**meprazole + **A**moxicillin + **M**etronidazole = H. pylori first-line in India. *Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Indian Academy of Gastroenterology H. pylori Guidelines.*
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.